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Abstract
Background—Guidelines recommend genetic counseling and testing for women with a pedigree 
suggestive of an inherited susceptibility for ovarian cancer. We evaluated the effect of referral to 
genetic counseling on genetic testing and prophylactic oophorectomy via a randomized controlled 
trial.
Methods—Data from an electronic mammography reporting system identified 12,919 women 
with a pedigree including breast cancer, of whom 625 were identified as high risk for inherited 
susceptibility to ovarian cancer using a risk assessment questionnaire. Of these, 458 women 
provided informed consent and were randomized 1:1 to intervention consisting of a genetic 
counseling referral (n=228) or standard clinical care (n=230).
Results—Participants were predominantly aged 45 to 65; 30% and 20% reported a personal 
history of breast cancer or a family history of ovarian cancer, respectively. Eighty-five percent of 
women in the intervention group participated in a genetic counseling session. Genetic testing was 
reported by 74 (33%) and 20 (9%) women in the intervention and control arms (p<0.005) 
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respectively. Five women in the intervention arm and two women in the control arm were 
identified as germline mutation carriers. Ten women in the intervention arm and three women in 
the control arm underwent prophylactic BSO (p<0.05).
Conclusion—Routine referral of women at high risk for ovarian cancer to genetic counseling 
promotes genetic testing and prophylactic surgery. Our findings from a randomized controlled trial 
demonstrate the value of implementing strategies targeting women at high risk for ovarian cancer 
to ensure they are offered access to recommended care.
Keywords
Ovarian cancer; Surgical prevention; Genetic counseling; Referral and Consultation; Risk 
Assessment and Genetic Testing
Introduction
Risk reducing salpingo-oophorectomy (RRSO) is an established epithelial ovarian cancer 
prevention strategy that reduces incidence dramatically in women at high genetic risk for the 
disease 1,2. A meta-analysis that included 10 studies demonstrated that RRSO reduces future 
risk of EOC in high-risk women by >80% 3. RRSO is recommended for all women with 
BRCA1/2 mutations between the ages of 35 and 40 once childbearing is complete4; it is also 
recommended around the age of menopause in women with mutations in DNA mismatch 
repair genes associated with hereditary non-polyposis colon cancer (Lynch Syndrome) 5-7.
Uptake of RRSO is low, perhaps because high-risk women are either unaware of their risk 8 
or perceive it inaccurately 9-11. Genetic counseling and genetic testing are important steps in 
assessing a woman's risk accurately 12 and identifying risk management strategies including 
RRSO 13. Evidence suggests that genetic counseling and testing services are under utilized 
14. Manual chart review has been proposed to identify candidates for genetic counseling 
referral 15, but it is costly relative to an automated search. Electronic family history data 
collection has been described 16, but not evaluated for hereditary breast-ovarian cancer 
syndrome families to our knowledge.
We conducted a randomized controlled trial to test whether a strategy using electronic 
medical records and questionnaires to systematic identify high-risk women for referral to 
genetic counseling could improve the uptake of risk-appropriate medical behaviors, 
including genetic testing and RRSO, compared to routine clinical care. We identified 458 
women at high-risk for ovarian cancer who provided informed consent and were randomized 
1:1 to genetic counseling referral (n=228) or standard clinical care (n=230).
Materials and Methods
Participant identification and recruitment
Electronic medical records were used to identify women who were potentially at high risk 
for carrying a deleterious cancer-predisposing gene mutation. We used routinely collected, 
self-reported family and medical history data stored in a Mammography Reporting System© 
(MRS) database to identify women with a personal or family history of breast cancer who 
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had a mammogram during a 28-month window between January 2006 and April 2008 at 
three Swedish Medical Center (SMC) facilities in Seattle, Washington. SMC is a large 
community-based hospital system that provides mammography screening to over 60,000 
women in King County, Washington annually. We identified 12,919 women aged 35-80 
reporting a personal or family history of breast cancer, no personal history of ovarian cancer, 
and no prior history of bilateral salpingo-oophorectomy (BSO). Each woman was mailed a 
study packet including an introductory letter from a SMC provider, a three-page Screening 
Questionnaire (SQ), and a consent form for future contact by study investigators. The letter 
explained that she was identified based on prior participation in mammography at SMC 
facilities, asked her to fill out and return the SQ, and offered her potential participation in 
cancer prevention research. The SQ assessed personal and family cancer history information 
that was not available in the MRS database.
Participant eligibility assessment and enrollment
Based on 2,797 responses to the SQ, 1,114 potentially eligible women were mailed a self-
administered Baseline Questionnaire (BQ) to confirm eligibility. The BQ assessed detailed 
family history, history of genetic testing, deleterious mutations identified by testing, use of 
breast and ovarian cancer screening services, current and prior use of oral contraception and 
menopausal hormone therapy, tubal sterilization, past gynecologic surgery including surgical 
indication and reproductive and menstrual history. Women were considered risk-eligible for 
the trial if they met pedigree criteria similar to those of the 2013 guidelines of the National 
Comprehensive Cancer Network (NCCN) 17 for referral to a genetic counselor. Personal 
history of triple negative breast cancer, family history of non-breast and non-ovarian cancers, 
and cancers in 3rd degree relatives were not specifically included. To ensure that all high-risk 
women retaining their ovaries were included, we did not exclude women reporting a 
deleterious mutation in BRCA1, BRCA2, genes related to Lynch syndrome (MLH1, PMS2, 
MSH2, MSH6), or TP53. We also included women with 1) a first or second-degree relative 
positive for Lynch Syndrome; 2) Ashkenazi Jewish ancestry with any family history of 
breast cancer among first or second-degree relatives; and 3) personal history, or a first-
degree relative, or multiple second-degree relatives with breast cancer diagnosed before age 
50. Women were ineligible if they 1) had a history of prior ovarian cancer or BSO; 2) had 
tested negative for a previously identified family germline mutation; 3) were unable or 
unwilling to provide informed consent; or 4) could not identify a primary care physician to 
receive reports from the genetic counselor. Women were not excluded based on prior genetic 
counseling or testing.
Of the 1,114 women contacted, 667 returned the BQ; 625 were confirmed to be eligible and 
invited to participate in an enrollment visit. Women were not provided individualized risk 
assessment information or more general information about ovarian cancer risk factors at the 
enrollment visit, but they were told that women with a personal history of breast cancer, or a 
family history of breast or ovarian cancer, may be at increased risk for developing ovarian or 
breast cancer. They were also informed that the purpose of the study was to evaluate the 
effects of referral for genetic counseling on medical decision-making related to cancer and 
cancer risk among women at increased risk for cancer. Interested women were asked to 
provide informed consent for randomization and study-related medical record review, and 
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informed that any costs associated with genetic testing during the study would be the 
responsibility of the participant and her insurance company. All study procedures were 
reviewed and approved by the Human Subjects Institutional Review Boards of the Fred 
Hutchinson Cancer Research Center and Swedish Medical Center in Seattle, WA, and 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki and Belmont Report. 
The trial was registered on http://www.clinicaltrials.gov. (Trial #NCT01851109). Of 625 
eligible women, 458 provided informed consent and were enrolled between July 2008 and 
December 2009.
Sample size
In the Ovarian Cancer Early Detection screening cohort 18, we had observed a 1% annual 
rate of RRSO among high-risk women receiving standard care. The trial was powered to 
detect a 4.5× increase in the rate of RRSO over two years from 2% in the control arm to 9% 
in the intervention arm. Target enrollment for the trial was 300 women per arm, yielding 
over 90% power to detect a difference of 7% in rate of RRSO.
Randomization
At enrollment, participants were randomized (by computer) 1:1 to an intervention arm 
(n=228) or a control arm (n=230) using a simple random allocation sequence provided by a 
statistician who was not involved in the collection of outcomes. Participants allocated to the 
intervention arm were invited to participate in a genetic counseling session as detailed 
below. Control arm women received routine care as directed by their primary health care 
provider, with no study-related intervention except follow-up outcome assessments. The 
study did not provide personalized risk assessment information, general information about 
ovarian cancer risk factors, or advice regarding ovarian cancer risk, to control-arm 
participants.
Intervention
Women allocated to the intervention arm were invited to participate in a standard clinical 
genetic counseling session at no cost. A typical session lasted approximately one hour and 
included a face-to face consultation with a certified genetic counselor. Counseling included 
review of the lifetime risk of breast and ovarian cancer for all women, an individualized 
discussion tailored to the participant's personal medical and family history, and 
determination of the need for genetic testing for the participant and/or her affected relative. 
Advantages and disadvantages of genetic testing were reviewed. Testing was usually 
arranged by the genetic counselor who tracked results and performed follow up for the 
proband and subsequently reviewed test results with the participant. Testing included 
selected analysis for mutations in BRCA1/2 and Lynch syndrome genes based on clinical 
indications. BRCA testing included screening for large scale rearrangements when indicated. 
Multi-gene panel tests which combine BRCA and Lynch gene testing with a range of other 
cancer pre-disposing genes into a single test based on a next generation sequencing platform 
were not available during the study period. The genetic counselor provided the patient's 
primary care provider with a summary of the counseling session, results of genetic testing if 
performed, and clinical options for risk management. For each intervention-arm participant, 
the genetic counselor documented 1) her attendance at a visit, 2) any recommendation made 
Drescher et al. Page 4













for mutation testing for her or her affected relative, 3) review with her of any genetic test 
results, and 4) any referral to a gynecologic oncologist or other provider to discuss RRSO.
Follow up
To ensure unbiased ascertainment of pelvic surgery during the study period, medical charts 
were reviewed by an abstractor who was blinded to study arm of the participant. In addition, 
questionnaires administered one and two years post-enrollment were used to obtain self-
reported follow-up information regarding genetic testing and pelvic surgery. Mailed follow 
up questionnaires were completed by 215 (94.3%) and 225 (97.8%) women in the 
intervention and control arms respectively. Women were asked to provide information 
regarding any pelvic surgery including bilateral or unilateral salpingo-oophorectomy 
performed for any indication as well as RRSO procedures for ovarian cancer prevention. 
Data abstraction was complete for all participants in 07/2013.
Outcomes ascertainment
Medical records from all participants identified through chart review to have had pelvic 
surgery were reviewed by the study nurse to ascertain the clinical indication for surgery, 
whether or not the surgery resulted in BSO, and the clinical indication for removing the 
ovaries and fallopian tubes. The study nurse, blinded to study arm of the participant, 
reviewed the pre-operative assessment by the surgeon, the operative note, and the pathology 
report. To further ensure lack of bias in ascertainment of outcomes, de-identified abstracted 
information for all instances of BSO was reviewed by the study gynecologic oncologist to 
classify all identified BSO procedures as either prophylactic or performed for other reasons. 
The procedure was considered prophylactic if either 1) the primary indication for pelvic 
surgery was RRSO, or 2) pelvic surgery was performed to treat a benign condition and the 
ovaries and fallopian tubes were removed solely to prevent cancer due to family history 
suggesting inherited susceptibility. BSO was considered not to be prophylactic if it was 
performed to treat any type of cancer or if there was any suspicion of ovarian cancer.
Analysis
Baseline characteristics of women were reported by study arm. The hypothesis of interest 
was tested using intent-to-treat proportional hazards analysis based on the assigned 
treatment at the time of randomization, comparing the rates of RRSO between women in the 
intervention and control arms. Observations were censored at 2 years post-enrollment 
(n=421), at the last available follow up (n=19), or at the time of BSO for non-prophylactic 
indications (n=5). Two-year cumulative incidence curves were generated and the Log-rank 
test was used to test significance of the difference in rates (hazards) of RRSO by study arm. 
All tests were two-tailed. Statistical analyses were performed using R software (Version 
3.1.0; The R Foundation for Statistical Computing, Seattle, WA). Cumulative incidence 
curves and the Log-rank test were calculated using the Survival package for R 19.
Results
Recruitment, enrollment and study outcomes by trial arm are shown in Figure 1. A total of 
12,919 women with a family or personal history of breast cancer were identified from 
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electronic mammography records and mailed an eligibility SQ. Five hundred fifty-two SQ 
mailings were returned to the study center with no forwarding address. Of the remaining 
12,367 SQ mailings, 2797 were completed and returned for an overall response rate of 23%. 
Of the 2797 SQ respondents, 1683 did not meet the study inclusion criteria. The remaining 
1114 SQ respondents were invited to complete the BQ. Of BQ mailings sent, 30 were 
returned to the study center with no forwarding address, 417 were not returned, 42 were 
completed by women who were found to be ineligible based on their responses, and 625 
were completed by apparently eligible women who were sent an invitation to attend an 
enrollment visit. Of these 625, one woman could not be contacted, 129 did not attend the 
clinic visit, and 37 were identified as ineligible during the enrollment interview. The 
remaining 458 women were enrolled in the trial. Randomization resulted in 228 and 230 
women allocated to the intervention and control arms respectively. Mean (standard 
deviation) follow-up time was 3.4 (0.9) and 3.5 (0.7) years in the intervention and control 
arms, respectively (p-value = 0.92, Log-Rank test).
Median age at enrollment was 54.1 and 51.8 years in the intervention and control arms 
respectively; 71 (31.1%) intervention-arm, and 65 (28.3%) control-arm, participants had a 
personal history of breast cancer. Clinical characteristics of participants at the time of 
enrollment are reported in Table 1; with the exception of minor variation in age distribution, 
they did not differ by study arm. Participants were predominantly Caucasian, college-
educated, parous, and never smokers. About 18% reported being of Ashkenazi Jewish 
descent. Two-thirds were between the ages of 45 and 65. About 77% had used hormonal 
contraception and 26% reported having used menopausal hormone therapy. Approximately 
30% had a personal history of breast cancer and 20% reported at least one relative with 
ovarian cancer. About 10% had undergone hysterectomy and 12% reported tubal ligation. 
Roughly 15% had prior mutation testing with 2 women in each arm reporting having a 
BRCA mutation.
Compliance with the intervention was 85%: per study records, 194 of 228 women in the 
intervention arm attended a trial-sponsored genetic counseling session. Use of genetic 
testing services during the study period was significantly higher among women in the 
intervention arm. Of 228 and 230 women allocated to the intervention and control arms 
respectively, 74 (32%) and 20 (9%) respectively reported having undergone genetic testing 
after the start of the trial (p<0.005). Five women in the intervention arm were identified as 
germline mutation carriers (4 BRCA, 1 MLH1) compared to 2 women with germline 
mutations (both BRCA) in the control arm.
Thirteen women (10 in the intervention arm and 3 in the control arm) underwent RRSO 
within two years of enrollment (Table 2). Blinded medical record review confirmed that in 
all 13 cases EOC prevention was the primary indication for removal of ovaries and fallopian 
tubes. The majority had no abnormalities found, and most also underwent hysterectomy. The 
median time to RRSO was 11 months in the intervention arm and 21 months in the control 
arm. The two-year incidence of RRSO was more than 3-fold higher in the intervention arm 
compared to the control arm (4.4% vs. 1.3%, respectively, from Kaplan-Meier estimates). 
Figure 2 presents the cumulative probability of RRSO in each of the study arms. The 
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hazards ratio was 3.44 (95% CI (Wald): 0.95 - 12.49) and the p-value for the Log-Rank test 
for the comparison of RRSO by study arm was 0.046.
Characteristics of all 18 participants who underwent any BSO procedure within 24 months 
of enrollment are described in Table 2. Among the 13 women having RRSO only three (all 
in the intervention arm) were under the age of 50. Six of the 13 women had a germline 
mutation including five women in the intervention arm and one in the control arm.
Four women including three in the intervention arm and one in the control arm underwent 
RRSO despite genetic test results that were negative for known deleterious mutations. All 
four had a personal history of breast cancer and at least one first or second-degree family 
member with breast cancer. Two of the four also had a family member with ovarian cancer 
including one with both breast and ovarian cancer. All were age 45 or older at the time of 
RRSO.
Three women (including two in the intervention arm and one in the control arm) opted for 
RRSO without prior genetic testing, including one who had RRSO in the context of surgery 
for pelvic relaxation. Two had a personal history of premenopausal breast cancer as well as 
family members with breast cancer. The woman without a personal history of breast cancer 
had a first-degree relative who was diagnosed with both breast and ovarian cancer.
The remaining five women had BSO for reasons other than risk reduction. One woman in 
each arm received BSO as treatment for breast cancer, another woman in each arm had BSO 
to address symptoms or test results that were suspicious for ovarian cancer, and one woman 
in the intervention arm underwent BSO as part of therapy for endometrial cancer.
Discussion
Results of this efficacy trial suggest that, compared to routine care, a strategy that includes 
systematic identification and referral to genetic counseling of high-risk women promotes 
genetic testing and prophylactic surgery to prevent ovarian cancer. In an intent-to-treat 
analysis, high-risk women offered genetic counseling underwent both genetic testing and 
RRSO at about 3.5 times the rate of women receiving routine care within a two-year follow-
up period. The background genetic testing rate in control group of 9% over 2 years women 
confirms prior reports that many high-risk women do not receive guideline recommended 
care 20. Fewer than 20% of eligible women reported having had genetic counseling, and 
most women (> 75%) were unaware of their elevated risk for ovarian cancer8. Among those 
that enrolled in the study, roughly 20% reported having a first or second-degree relative with 
ovarian cancer and therefore meet current guidelines for genetic testing4.
Compliance with the genetic counseling referral was good at 85%, possibly in part because 
it was offered at no cost during the trial. About 1/3 of women in the intervention arm had 
genetic testing, a rate that is consistent with other studies that report between 26% and 55% 
of breast cancer family members attending high-risk clinics opt for testing 21,22. Costs have 
been reported as an obstacle to BRCA testing 23. In our study insurance coverage was 
verified before the testing was performed. Insurers' guidelines varied and some insurers 
covered testing for affected women only. Full price of the genetic test was about $3000 but 
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cost was a deterrent to only a few women because out-of-pocket costs seldom exceeded 
$200. The recommendation that an affected family member be tested to definitively interpret 
results was a barrier for some unaffected women as an affected family member was not 
always available for testing. Targeting other factors associated with the decision to proceed 
with genetic testing such as age, personal cancer history, race and psychosocial issues 23-26 
may improve genetic testing rates.
The rate of RRSO in the intervention arm was increased more than 3-fold (p<0.05). Five of 
the ten intervention arm women who underwent RRSO had a deleterious mutation at the 
time of the procedure. The benefits of RRSO for mutation carriers are well documented. The 
role of RRSO in women without a documented mutation is less clear. Women who test 
negative for a mutation segregating in the family are not at increased risk. However not all 
cancer families are explained by the known susceptibility genes and many women choose to 
forgo genetic testing. Since this study was conducted, several new ovarian cancer 
susceptibility genes have been identified including RAD51D, RAD51C, BRIP1, PALB2 and 
BARD1 27-29; clinical testing for mutations in some of these genes is now available. Recent 
guideline updates now include a recommendation that BRIP1, RAD51 and RAD51C 
mutation carriers consider RRSO4.
The 2-year follow-up period of the study is consistent with other studies evaluating 
procedure choice in high-risk women, but some women may have undergone RRSO outside 
of this follow-up interval. Studies suggest that most women who opt for RRSO undergo the 
procedure shortly after learning the results of genetic testing. For example, in a cohort study 
of 272 BRCA mutation carriers the median time from receiving genetic test results to 
surgery in patients undergoing RRSO was 123 days with an Inter-quartile range (IQR) of 
56-331 days 30. In a separate cohort of 244 mutation carriers, the median time to RRSO 
was .75 years (IQR .41 to 2.10)31 Consistent with this data, the median time from 
enrollment to RRSO in our study was 11 months and 21 months in the intervention and 
control arms respectively. Intervention-arm women were offered genetic counseling 
immediately after study enrollment. The delay in time to RRSO in control-arm women may 
reflect in part the additional time it took for women receiving usual care to be referred to 
genetic counseling and/or learn about their risk.
Data available to us electronically were intended for assessment of breast cancer risk and as 
an aid in interpretation of mammography results. Consequently additional steps were 
required to identify women at high genetic risk for ovarian cancer. Overall it was necessary 
to contact 12,919 women to identify 625 potentially eligible women for this study, largely 
because of incomplete risk assessment at the time of mammography. A more comprehensive 
risk assessment tool that includes questions about ovarian cancer family history would 
simplify the identification of women at high risk for both ovarian and breast cancer. It is not 
known how many mammography facilities in the U.S. do comprehensive cancer risk 
assessment at the time of mammography, or to what extent electronic data are available for 
this purpose.
In summary, our results from a randomized controlled trial demonstrate that risk-appropriate 
use of genetic testing and surgical prevention strategies can be enhanced by systematic 
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identification and referral of women at high risk for a deleterious genetic mutation to a 
genetic counselor. The approach has public health potential to reduce ovarian cancer 
incidence in women at greatest risk. These findings motivate action to design and implement 
efficient strategies to ensure that high-risk women are identified and offered access to 
currently available and recommended care13.
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Figure 1. Flow diagram of participants at each phase of the study
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Figure 2. Cumulative incidence curves illustrating time to prophylactic bilateral salpingo- 
oophorectomy from randomization by study arm
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Table 1
Baseline characteristics of trial participants by study arm
Category Variable / Value Control Arm Intervention Arm
Sample Size 230 228
Age Mean (SD) 53 (10) 54 (10)
Age (Categorical) 35 ≤ age ≤ 44 43 (18.7%) 43 (18.9%)
45 ≤ age ≤ 54 109 (47.4%) 86 (37.7%)
55 ≤ age ≤ 64 47 (20.4%) 72 (31.6%)
65 ≤ age < 90 31 (13.5%) 27 (11.8%)
BMI (kg/m2) Mean (SD) 23 (5) 23 (5)
Race* Black or African American 3 (1.3%) 0 (0.0%)
White or Caucasian 163 (70.7%) 152 (66.7%)
Asian 8 (3.5%) 10 (4.4)
Other 2 (0.9%) 1 (0.4%)
Ashkenazi Jewish Ethnicity* Yes 36 (15.7%) 34 (14.9%)
No 157 (68.3%) 153(67.1)
Education* Some high school 0 (0.0%) 1 (0.4%)
High school graduate or GED 5 (2.2%) 9 (3.9%)
Some college or technical school 45 (19.6%) 37 (16.2%)
Graduated college or beyond 178 (77.4%) 177 (77.6%)
Smoking Prior Smoker 66 (28.7%) 79 (34.6%)
Current Smoker 12 (5.2%) 9 (3.9%)
Never Smoker 152 (66.1%) 140 (61.4%)
Hysterectomy* Yes 18 (7.9%) 26 (11.4%)
No 210 (91.3%) 198 (86.8%)
Tubal Ligation* Yes 24 (10.4%) 29 (12.7%)
No 205 (89.1%) 197 (86.4%)
Hormonal Contraception Used for < 1 year 26 (11.3%) 24 (10.5%)
Used for ≥ 1 year 152 (66.1%) 149 (65.4%)
Never Used 52 (22.6%) 55 (24.1%)
Menopausal Hormone Therapy* Used for < 1 year 17 (7.4%) 21 (9.2%)
Used for ≥ 1 year 34 (14.8%) 35 (15.4%)
Never Used 154 (67.0%) 150 (65.7%)
Parity Nulliparous 81 (35.2%) 81 (35.5%)
Parous 149 (64.8%) 147 (64.5%)
Mammogram (every two years) Yes 229 (99.6%) 227 (99.6%)
No 1 (0.4%) 1 (0.4%)
Ultrasound of Ovaries* (every two years) Yes 74 (32.2%) 90 (39.5%)
No 146 (63.5%) 133 (58.3%)
Prior Genetic Testing* Yes 37 (16.1%) 31 (13.6%)
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Category Variable / Value Control Arm Intervention Arm
No 192 (83.5%) 195 (85.5%)
BRCA1/2 Mutation * Yes 2 (0.9%) 2 (0.9%)
No 3 (1.3%) 0 (0.0%)
Unknown 32 (13.9%) 29 (12.7)
Mutations in First and Second-Degree Relatives* BRCA1/2 10 (4.3%) 4 (1.8%)
Deleterious Mutation 5 (2.2%) 3 (1.3%)
Variant of Unknown Significance 5 (2.2%) 1 (0.4%)
Unknown 210 (91.3%) 211 (92.5%)
Personal History of Cancer* Breast Cancer 58 (25.2%) 65 (28.5%)
Other Cancer 27 (11.7%) 23 (10.1%)
Breast and Other Cancer 7 (3.0%) 6 (2.6%)
None 138 (60.0%) 134 (58.8%)
No. of Relatives with Ovarian Cancer** 0 179 (77.8%) 183 (80.7%)
1 42 (18.3%) 37 (16.2%)
2 7 (3.0%) 5 (2.2%)
3+ 2 (0.9%) 2 (0.9%)
No. of Female Relatives with Breast Cancer** 0 28 (12.2%) 29 (12.7%)
1 98 (42.6%) 96 (42.1%)
2 60 (26.1%) 59 (25.9%)
3+ 44 (19.1%) 44 (19.3%)
*
Numbers do not add to study arm total due to missing data
**
Counts include first and second-degree relatives
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